EGFR and non-small cell lung carcinoma: With the rapid evolution of molecular targeted therapy, the survival of non-small cell lung cancer (NSCLC) patients with mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations, has improved significantly.